Affiliation:
1. National Centre for Advanced Tribology at Southampton, Faculty of Engineering and Physical Sciences, University of Southampton, Southampton SO17 1BJ, UK
Abstract
We aim to develop new portable desktop tissue analysers (DTAs) to provide fast, low-cost, and precise test results for fast nanomechanical profiling of tumours. This paper will explain the reasoning for choosing indentation-type atomic force microscopy (IT-AFM) to reveal the functional details of cancer. Determining the subtype, cancer stage, and prognosis will be possible, which aids in choosing the best treatment. DTAs are based on fast IT-AFM at the size of a small box that can be made for a low budget compared to other clinical imaging tools. The DTAs can work in remote areas and all parts of the world. There are a number of direct benefits: First, it is no longer needed to wait a week for the pathology report as the test will only take 10 min. Second, it avoids the complicated steps of making histopathology slides and saves costs of labour. Third, computers and robots are more consistent, more reliable, and more economical than human workers which may result in fewer diagnostic errors. Fourth, the IT-AFM analysis is capable of distinguishing between various cancer subtypes. Fifth, the IT-AFM analysis could reveal new insights about why immunotherapy fails. Sixth, IT-AFM may provide new insights into the neoadjuvant treatment response. Seventh, the healthcare system saves money by reducing diagnostic backlogs. Eighth, the results are stored on a central server and can be accessed to develop strategies to prevent cancer. To bring the IT-AFM technology from the bench to the operation theatre, a fast IT-AFM sensor needs to be developed and integrated into the DTAs.
Reference101 articles.
1. WHO (2024, January 20). Fact Sheet. Available online: https://www.who.int/news-room/fact-sheets/detail/cancer.
2. Identifying research priorities in breast cancer surgery: A UK priority setting partnership with the James Lind Alliance;Potter;Breast Cancer Res. Treat.,2023
3. (2024, January 20). Breast Cancer Now. Breast Cancer: Facts and Figures. Available online: https://breastcancernow.org/sites/default/files/breast_cancer_facts_and_figures_-_final.pdf.
4. NICE (2021). 2021 Exceptional Surveillance of Suspected Cancer: Recognition and Referral (NICE Guideline NG12) and Suspected Neurological Conditions: Recognition and Referral (NICE Guideline NG127), NICE.
5. New technologies in breast cancer sentinel lymph node biopsy; from the current gold standard to artificial intelligence;Cykowska;Surg. Oncol.,2020